Europe Immunoassay Analyzers Market Insights Forecasts to 2033

• The Europe Immunoassay Analyzers Market Size was valued at USD 1.9 Billion in 2023.
• The Market Size is Growing at a CAGR of 5.99% from 2023 to 2033
• The Europe Immunoassay Analyzers Market Size is Expected to Reach USD 3.4 Billion by 2033

The Europe Immunoassay Analyzers Market is Anticipated to Reach USD 3.4 Billion by 2033, growing at a CAGR of 5.99% from 2023 to 2033.

Market Overview

An immunoassay analyzer is a device that detects and measures the concentration of specific substances in a sample, such as blood, urine, saliva, or cerebrospinal fluid (CSF). They use antibodies as reagents to perform a variety of tests, including detecting protein, bacterial, or viral toxins, measuring drug concentration, testing for infectious diseases, testing for allergies and endocrine hormones, measuring cardiac markers, and measuring hormone levels such as growth hormones or thyroid hormones. Immunoassay analyzers use a variety of methodologies, including immunoprecipitation, particle immunoassays, immunonephelometry, radioimmunoassay, enzyme immunoassay, fluorescent immunoassay, and chemiluminescent immunoassays. Immunoassay analyzers are used in Europe for various purposes. For example, the ETA-Scan is used by more than 3,000 practitioners in Europe to determine the health status of patients. Radioimmunoassay has been used commercially in Europe to analyze progesterone levels in milk. The European immunoassay analyzers market is primarily driven by the increasing prevalence of chronic diseases, such as cancer and infectious diseases, which necessitate accurate and rapid diagnostic tools.

Report Coverage

This research report categorizes the market for the Europe immunoassay analyzers market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Europe immunoassay analyzers market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Europe immunoassay analyzers market.

Driving Factors

The growing aging population, alongside advancements in technology that enhance the sensitivity and specificity of immunoassays, fuels market growth. Additionally, the rising demand for point-of-care testing and home healthcare solutions reflects a shift towards more accessible and efficient diagnostic methods. Regulatory support and investments in research and development also contribute significantly, enabling healthcare providers to adopt innovative immunoassay technologies that improve patient outcomes.

Restraining Factors

The Europe immunoassay analyzers market faces several challenging factors that could hinder its growth. High costs associated with advanced immunoassay technologies and the necessary infrastructure can limit accessibility, particularly in developing regions. Additionally, the complex regulatory environment and stringent approval processes for new diagnostic devices can slow down market entry for innovative products. 

Market Segmentation

The Europe immunoassay analyzers market share is classified into analyzers and end-use.

• The enzyme immunoassay (EIA) analyzers segment is expected to hold the largest market share through the forecast period.

The Europe immunoassay analyzers market is segmented by analyzers into enzyme immunoassay (EIA) analyzers, radioimmunoassay (RIA) analyzers, and others. Among these, enzyme immunoassay (EIA) analyzers segment is expected to hold the largest market share through the forecast period. The application of EIA analyzers is widespread in bioanalytical, industrial, and healthcare settings, making them the most extensively used immunodiagnostic system. These analyzers rely on the reactivity of enzyme assays and the specificity of antibodies to detect and quantify molecules like antibodies, peptides, proteins, and hormones.   

• The hospitals segment is expected to dominate the Europe immunoassay analyzers market during the forecast period.

Based on the end-use, the Europe immunoassay analyzers market is divided into hospitals, blood banks, clinical laboratories, pharmaceutical and biotech companies, academic research centers, and others. Among these, the hospitals segment is expected to dominate the Europe immunoassay analyzers market during the forecast period. Hospitals are experiencing a surge in demand for immunoassay products due to the rising number of hospitalizations caused by chronic and infectious diseases. The market for automated immunoassay analyzers is also being propelled by the growing presence of corporate hospital chains.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Europe immunoassay analyzers market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Siemens Healthineers
• bioMérieux SA
• Abbott Laboratories
• Danaher Corporation (Beckman Coulter)
• Quidel Corporation
• Ortho Clinical Diagnostics
• Sysmex Corporation
• Bio-Rad Laboratories, Inc.
• Becton, Dickinson and Company
• F. Hoffmann-La Roche AG
• Thermo Fisher Scientific, Inc.
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2024, Roche launches B-cell lymphoma diagnostic assay in Europe. Roche’s Ventana B-cell lymphoma diagnostic assay can detect and differentiate B-cell lymphomas and plasma cell neoplasms from a normal immune response.

• In May 2024, Beckman Coulter Diagnostics, a global leader in clinical diagnostics, and MeMed, a leader in the emerging field of advanced host-response technologies, announced expansion of their host immune response diagnostics partnership. Beckman Coulter is an authorized distributor of the MeMed BV assay, a rapid immunoassay test able to distinguish between bacterial and viral infections, and MeMed Key, a compact immunoassay analyzer cleared to run the MeMed BV assay in the United States and Europe.

Market Segment

This study forecasts revenue at Europe, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Europe Immunoassay Analyzers Market based on the below-mentioned segments:

Europe Immunoassay Analyzers Market, By Analyzers

• Enzyme Immunoassay (EIA) Analyzers
• Radioimmunoassay (RIA) Analyzers
• Others

Europe Immunoassay Analyzers Market, By End-Use

• Hospitals
• Blood Banks
• Clinical Laboratories
• Pharmaceutical and Biotech Companies
• Academic Research Centers
• Others